Literature DB >> 6425039

Conformational energy studies and in vitro and in vivo activity data on growth hormone-releasing peptides.

F A Momany, C Y Bowers, G A Reynolds, A Hong, K Newlander.   

Abstract

A series of growth hormone-releasing peptides have been designed and tested for both in vitro and in vivo activity. In vitro activity at 1-10 ng/ml was obtained for the pentapeptide, His-DTrp-Ala-Trp-DPhe-NH2 (I) and the hexapeptide, His-DTrp-Ala-Trp-DPhe-Lys-NH2 (II). These peptides, as well as others to be described, are active in releasing GH in vivo at low microgram dosages. In this manuscript, the conformational properties and in vitro and in vivo activity of a series of small peptides are reported. Results of the biological studies are reported in an accompanying paper.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6425039     DOI: 10.1210/endo-114-5-1531

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  7 in total

Review 1.  Interactive regulation of postmenopausal growth hormone insulin-like growth factor axis by estrogen and growth hormone-releasing peptide-2.

Authors:  J D Veldhuis; W S Evans; C Y Bowers; S Anderson
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.633

2.  The effects of a continuous infusion of hexarelin on pulsatile growth hormone release, growth axis and galanin gene expression and on the response of the growth axis to growth hormone-releasing hormone.

Authors:  L K Conley; R S Brogan; A Giustina; W B Wehrenberg
Journal:  Pituitary       Date:  2000-05       Impact factor: 4.107

3.  Growth hormone secretagogues: characterization, efficacy, and minimal bioactive conformation.

Authors:  R S McDowell; K A Elias; M S Stanley; D J Burdick; J P Burnier; K S Chan; W J Fairbrother; R G Hammonds; G S Ingle; N E Jacobsen; D L Mortensen; T E Rawson; W B Won; R G Clark; T C Somers
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

4.  Influence of beta-adrenergic agonists and antagonists on the GH-releasing effect of Hexarelin in man.

Authors:  E Arvat; L Gianotti; J Ramunni; L DiVito; R Deghenghi; F Camanni; E Ghigo
Journal:  J Endocrinol Invest       Date:  1996-01       Impact factor: 4.256

5.  Arginine enhances the growth hormone-releasing activity of a synthetic hexapeptide (GHRP-6) in elderly but not in young subjects after oral administration.

Authors:  E Ghigo; E Arvat; G Rizzi; J Bellone; M Nicolosi; G M Boffano; M Mucci; M F Boghen; F Camanni
Journal:  J Endocrinol Invest       Date:  1994-03       Impact factor: 4.256

6.  Growth hormone-releasing activity of hexarelin in humans. A dose-response study.

Authors:  B P Imbimbo; T Mant; M Edwards; D Amin; N Dalton; F Boutignon; V Lenaerts; P Wüthrich; R Deghenghi
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

7.  Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue.

Authors:  A A Patchett; R P Nargund; J R Tata; M H Chen; K J Barakat; D B Johnston; K Cheng; W W Chan; B Butler; G Hickey
Journal:  Proc Natl Acad Sci U S A       Date:  1995-07-18       Impact factor: 11.205

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.